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refractory follicular lymphoma, diffuse large B cell lym-
phoma and lymphoplasmacytic lymphoma and upfront
consolidation for mantle cell lymphoma. 8 (36.4%) pts
underwent AutoSCT as consolidative therapy and 14
(63.6%) pts for relapsed/refractory disease. Therapies prior
to AutoSCT were 1-3 regimens. Time to engraftment was
11.71.79 days for neutrophils and 15.322.6 days for
platelets. Be-EAM-related toxicities included nausea,
emesis, diarrhea, neutropenic fever and mucositis. 13
(59%) pts had severe mucositis (Grade 3/4) with 5 pts
developing neutropenic enterocolitis including 1 patient
with pneumatosis intestinalis. Overall, 18 (81.8%) pts were
in CR and 2 (9%) pts had minimal disease at D100. 5
(22.7%) pts had relapsed disease. 4 (18.2%) pts died from
relapsed or progressive disease.
Conclusion: Bendamustine based conditioning is an effec-
tive regimen in patients with NHL undergoing autologous
stem cell transplantation as previously reported. It has the
potential of causing severe mucositis irrespective of age,
comorbidities, disease type or number of prior therapies.
This regimen although moderately tolerated should be used
cautiously especially in patients who have had prior thera-
pies that can affect the gastrointestinal tract.166
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Introduction: We have previously shown that as
compared with chemo-mobilization (CHM) cytokine
mobilization (CTM) is associated with a better chance ofTable 1
Primary Endpoint Analysis
Chemo-
mobilization
(N[19)
Cytokine
mobilization
(N[55)
p-value
Median total CD34 cells/kg
collected (in millions/kg):
Myeloma 14.9 8.37 0.01
Non-myeloma 4.47 5.03 0.71
Median number of apheresis
days (mean):
Myeloma 1 (1.75) 1 (1.76) 0.99
Non-myeloma 2 (1.67) 1 (1.59) 0.89
Target dose achieved: 0.05
Yes 16 (84.2%) 51 (92.7%)
No 3 (15.8%) 4 (7.3%)
Median day 1 CD34 collection
(in millions/kg):
0.01
Myeloma NA 6.86
Non-myeloma NA 3.67achieving a target autologous stem cell dose for patients
with multiple myeloma (MM). We now review our expe-
rience of autologous stem cell mobilization using a similar
strategy for all patients referred for an autologous trans-
plant (auto-SCT).
Methods: We analyzed consecutive patients who received
an auto-SCT for hematological malignancies at our center
from July 2010 to June 2013. CHM was achieved with
cyclophosphamide (4 g/m2), pegﬁlgrastim (12 mg) and
plerixafor (0.24 mg/kg once daily until target dose
collected or maximum of 4 days apheresis). CTM was
achieved with pegﬁlgrastim and plerixafor. We recorded
the total CD34+ cells/kg collection, number of apheresis
days, and if the prescribed dose of CD34+ cells/kg was
achieved. The prescribed cell dose in patients with MM is
6.0 x 106/kg, and 3.0 x 106/kg for all other hematological
malignancies. We compared the median total CD34+ cells/
kg dose collection (Wilcoxon test), the mean number of
apheresis days (Poission), and target stem cell dose
collection (non-inferiority test on two proportions). We
also compared day 1 stem cell collection in the CTM
group based on disease (myeloma vs. non-myeloma)
(Wilcoxon test). Finally, we analyzed the probability of
successful stem cell dose collection if the target collection
dose was higher than our own criteria.
Results: A total of 74 patients were included. Fifty-three
patients had a diagnosis of MM and twenty-one patients had
other hematological malignancies, non-Hodgkin (n¼15) and
Hodgkin lymphoma (n¼2). There was no statistically signif-
icant difference in age, gender, number of prior induction
treatment, prior treatment with lenalidomide and time from
diagnosis to transplant between the two groups. In the CHM
group, 7 (47%) were hospitalized from complications of
mobilization regimen, whereas no patients were hospital-
ized in the CTM group (p<0.001). There was no statistically
signiﬁcant difference in neutrophil or platelet engraftment
between CHM and CTM. Multivariate analysis did not reveal
predictive factors which lead to>1 apheresis attempts. Table
1 describes the primary outcomes.
Conclusion: Cytokine-mobilization with pegﬁlgrastim and
planned plerixafor is an effective strategy for stem cell mobi-
lization in patients being considered for autologous transplant.
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Background: Serum biomarkers in classical Hodgkin Lym-
phoma (cHL) reﬂect both tumor biology and burden in the
non-transplant setting.We sought to determine the prognostic
value of cHL serum biomarkers in predicting early relapse
following autologous stem cell transplantation (ASCT).
